Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
It contains Semaglutide base, a Food and Drug Administration (FDA)-approved Glucagon-Like Peptide-1 (GLP-1) receptor agonist
Studies of semaglutide and hypothyroidism subgroups in weight-loss trials have shown comparable efficacy and safety to non-hypothyroid participants, with no pharmacodynamic antagonism documented
Because weight loss is a highly personal experience, we also ensure that your injection pens are delivered discreetly in plain packaging, protecting your privacy
Adverse effects observed in trials include: Nausea and vomiting particularly during dose escalation Diarrhoea or constipation Decreased appetite Injection site reactions Fatigue and dizziness Gallbladder-related events (including gallstones), consistent with effects observed with other GLP-1based therapies [9] Rare cases of pancreatitis , a risk associated with the GLP-1 receptor agonist class [10] [3] Because retatrutide is not licensed in the UK, the MHRA has not issued specific prescribing or dosing guidance for this compound
